ReviewTaiwan journal of ophthalmology
Basic science review of birth tissue uses in ophthalmology.
Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- CLARIX FLO Inhibits DRG Adhesion-Induced Neuropathic Pain Through the CD44-TRPV1 Signaling Pathway.International journal of molecular sciences · 2026Article
- Superficial Keratectomy with Cryopreserved Amniotic Membrane for Ocular Surface Optimization in Patients with Epithelial Basement Membrane Dystrophy.Clinical optometry · 2026Article
- Management of Stage 1 Neurotrophic Keratopathy with Shelf-Stable, Cryopreserved Amniotic Membrane: A Retrospective Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Adjunctive Cryopreserved Amniotic Membrane for Recalcitrant Keratopathy: Long-Term Outcomes with Maintenance Therapy.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Use of an Eyelid Pressure Patch Concomitantly with a Decellularized Dehydrated Amniotic Membrane for Ocular Surface Disease Management.Ophthalmology and therapy · 2025Article
- Therapeutic Outcomes of Shelf-Stable, Cryopreserved Amniotic Membrane in Recalcitrant Keratopathy.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Shelf-Stable, Cryopreserved Amniotic Membrane for the Management of Ocular Surface Disease: A Retrospective Assessment.Clinical optometry · 2025Article
- Article
- Article
- Human birth tissue products as a non-opioid medicine to inhibit post-surgical pain.bioRxiv : the preprint server for biology · 2024Article
- Dr. Scheffer C.G. Tseng: A Pioneer in Cryopreserved Amniotic Membrane for Regenerative Medicine.Cureus · 2024Review
- Outcomes of transforaminal epidural injection of amniotic membrane/umbilical cord particulate for lumbar radiculopathy: a case series.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- Therapeutic efficacy and short-term durability of trans-urethral amniotic bladder injections for the treatment of refractory COVID-associated cystitis.Bladder (San Francisco, Calif.) · 2024Article
- The Preparation and Clinical Efficacy of Amnion-Derived Membranes: A Review.Journal of functional biomaterials · 2023Review
- Review
- Early three-month report of amniotic bladder therapy in patients with interstitial cystitis/bladder pain syndrome.International urology and nephrology · 2023Article
- Distribution of an analgesic palmitoylethanolamide and other N-acylethanolamines in human placental membranes.PloS one · 2023Article
- Association of Treatment Duration and Clinical Outcomes in Dry Eye Treatment with Sutureless Cryopreserved Amniotic Membrane.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Preparation of human amniotic membrane for transplantation in different application areas.Frontiers in transplantation · 2023Review
- Pilot study of a glue-less, suture-less amniotic membrane for pterygium excision.International ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The birth tissue is predominantly comprised of amniotic membrane (AM) and umbilical cord (UC), which share the same cell origin as the fetus. These versatile biological tissues have been used to treat a wide range of conjunctival and corneal conditions since 1940. The therapeutic benefits of the birth tissue stem from its anti-inflammatory and anti-scarring properties that orchestrate regenerative healing. Although the birth tissue also contains many cytokines, growth factors, and proteins, the heavy chain 1-hyaluronic acid/pentraxin 3 (HC-HA/PTX3) matrix has been identified to be a major active tissue component responsible for AM/UC's multifactorial therapeutic actions. HC-HA/PTX3 complex is abundantly present in fresh and cryopreserved AM/UC, but not in dehydrated tissue. In this review, we discuss the tissue anatomy, the molecular mechanism of action based on HC-HA/ PTX3 to explain their therapeutic potentials, and the various forms available in ophthalmology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.